Takada K, Hayashi M, Takahashi K, Yasui S
Jpn Circ J. 1986 Nov;50(11):1055-61. doi: 10.1253/jcj.50.1055.
The cause of pulmonary hypertension in chronic obstructive pulmonary disease (COPD) is considered to be hypoxic pulmonary vasoconstriction, which may be mediated in part by angiotensin II. We administered captopril (25 mg, orally) to seven patients with COPD and complicating cor pulmonale in stable state. Hemodynamic responses were recorded before and one hour after the administration of the drug. Captopril increased cardiac output by 23% (p less than 0.025) and reduced mean systemic pressure by 12% (p less than 0.004), but did not alter mean pulmonary arterial pressure. Pulmonary and systemic vascular resistance fell, respectively, by 14% (p less than 0.035) and 31% (p less than 0.03). There was an increase in pulmonary/systemic vascular resistance ratio (p less than 0.007). Heart rate, mean right atrial, pulmonary capillary wedge pressure, arterial oxygen tension and dioxide tension, and alveolar- arterial oxygen tension difference remained unchanged. These results suggest that captopril is successful in reducing pulmonary vascular resistance without affecting arterial blood gases, but does not change mean pulmonary arterial pressure probably because of the concurrent increase in pulmonary blood flow. In addition, results indicate that captopril has more effects on the systemic vasculature than on the pulmonary circulation.
慢性阻塞性肺疾病(COPD)所致肺动脉高压被认为是由缺氧性肺血管收缩引起的,而血管紧张素II可能在其中起到了部分介导作用。我们对7例处于稳定期的COPD合并肺心病患者口服卡托普利(25毫克)。在给药前及给药1小时后记录血流动力学反应。卡托普利使心输出量增加了23%(p<0.025),使平均体循环压力降低了12%(p<0.004),但未改变平均肺动脉压。肺血管阻力和体循环血管阻力分别下降了14%(p<0.035)和31%(p<0.03)。肺/体循环血管阻力比值增加(p<0.007)。心率、平均右心房压、肺毛细血管楔压、动脉血氧分压和二氧化碳分压以及肺泡-动脉血氧分压差均无变化。这些结果表明,卡托普利可成功降低肺血管阻力而不影响动脉血气,但可能由于肺血流量同时增加,故未改变平均肺动脉压。此外,结果表明卡托普利对体循环血管系统的作用比对肺循环的作用更大。